Patents by Inventor Raffaele Ingenito

Raffaele Ingenito has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240150405
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Application
    Filed: October 23, 2023
    Publication date: May 9, 2024
    Inventors: Chengzao SUN, Brian Troy FREDERICK, Sandeep SOMANI, Gregory Thomas BOURNE, Raymond PATCH, Ashok BHANDARI, Raffaele INGENITO, Roberto COSTANTE, Danila BRANCA, Elisabetta BIANCHI
  • Patent number: 11932705
    Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: March 19, 2024
    Assignees: MERCK SHARP & DOHME LLC, RA PHARMACEUTICALS, INC.
    Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
  • Publication number: 20230303625
    Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
    Type: Application
    Filed: September 27, 2022
    Publication date: September 28, 2023
    Applicant: Ra Pharmaceuticals, Inc.
    Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole HA, Hyewon Youm, Mark W. EMBREY, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. GILBERT, Aurash Shahripour, Yusheng Xiong
  • Patent number: 11725036
    Abstract: A biologically active single chain Relaxin peptide having the formula Nter-Ac-L-E-G-R-E-K-V-R-A-X19-I-X21-X22-E-G-X25-S-T-F-S-X30-R-A-X33-NH2-Cter, or a salt of solvate thereof, is described.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: August 15, 2023
    Assignee: Sanofi
    Inventors: Olivier Duclos, Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
  • Publication number: 20230122330
    Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
    Type: Application
    Filed: August 29, 2022
    Publication date: April 20, 2023
    Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
  • Publication number: 20220402983
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Application
    Filed: January 14, 2021
    Publication date: December 22, 2022
    Inventors: Chengzao Sun, Brian Troy Frederick, Sandeep Somani, Ashok Bhandari, Raymond Patch, Stephanie Barros, Raffaele Ingenito, Roberto Costante, Danila Branca, Elisabetta Bianchi
  • Patent number: 11530244
    Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: December 20, 2022
    Assignees: Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.
    Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
  • Patent number: 11505575
    Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: November 22, 2022
    Assignees: Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.
    Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
  • Patent number: 11306125
    Abstract: Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R4, and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: April 19, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yusheng Xiong, Thomas Joseph Tucker, Chengwei Wu, Elisabetta Bianchi, Danila Branca, Angela Dawn Kerekes, Abbas M. Walji, Hubert B. Josien, Fa-Xiang Ding, Hyewon Youm, Alessia Santoprete, Raffaele Ingenito
  • Publication number: 20210292387
    Abstract: The present invention relates to a biologically active single chain Relaxin peptide having the following formula (I) (SEQ ID NO 105): Nter-AC-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S- X27-X28-X29-X30-X31-X32-X33-NH2-Cter or a salt or solvate thereof. It also concerns a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.
    Type: Application
    Filed: October 30, 2020
    Publication date: September 23, 2021
    Inventors: Olivier DUCLOS, Stéphane ILLIANO, Sergio MALLART, Claire MINOLETTI-HOCHEPIED, Elisabetta BIANCHI, Raffaele INGENITO, Paola MAGOTTI, Alessia SANTOPRETE
  • Publication number: 20210284694
    Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
    Type: Application
    Filed: June 20, 2019
    Publication date: September 16, 2021
    Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
  • Publication number: 20210261622
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Application
    Filed: January 14, 2021
    Publication date: August 26, 2021
    Inventors: Chengzao Sun, Brian Troy Frederick, Sandeep Somani, Gregory Thomas Bourne, Raymond Patch, Ashok Bhandari, Raffaele Ingenito, Roberto Costante, Danila Branca, Elisabetta Bianchi
  • Publication number: 20210214395
    Abstract: Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R4, and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g.
    Type: Application
    Filed: June 20, 2019
    Publication date: July 15, 2021
    Inventors: Yusheng Xiong, Thomas Joseph Tucker, Chengwei Wu, Elisabetta Bianchi, Danila Branca, Angela Dawn Kerekes, Abbas M. Walji, Hubert B. Josien, Fa-Xiang Ding, Hyewon Youm, Alessia Santoprete, Raffaele Ingenito
  • Publication number: 20210163538
    Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
    Type: Application
    Filed: June 20, 2019
    Publication date: June 3, 2021
    Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
  • Patent number: 10988524
    Abstract: Provided is a biologically active single chain Relaxin peptide having the following formula (I): Nter-X-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(X34)d-NH2-Cter. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, or a pharmaceutically acceptable salt or a solvate thereof. Further provided is the peptide, a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition for use as a medicament.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 27, 2021
    Assignee: SANOFI
    Inventors: Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Frank Marguet, Olivier Duclos, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
  • Patent number: 10988523
    Abstract: Provided is a biologically active single chain Relaxin peptide having the following formula (I): Nter-Ac-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(K)d-(X35)e-(gE)f-X37-Cter; or a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 27, 2021
    Assignee: SANOFI
    Inventors: Denis Brasseur, Olivier Duclos, Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Frank Marguet, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
  • Patent number: 10961295
    Abstract: Provided is a biologically active single chain Relaxin peptide having the following formula (I) (SEQ ID NO 105): Nter-Ac-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-X31-X32-X33-NH2-Cter or a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one biologically active single chain Relaxin peptide. Uses of the peptide or the pharmaceutical composition as a medicament are also provided.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: March 30, 2021
    Assignee: SANOFI
    Inventors: Olivier Duclos, Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
  • Publication number: 20190233494
    Abstract: The present invention relates to a biologically active single chain Relaxin peptide having the following formula (I) (SEQ ID NO 105): Nter-Ac-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30—X31—X32—X33—NH2—Cter or a salt or solvate thereof. It also concerns a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 1, 2019
    Inventors: Olivier DUCLOS, Stéphane ILLIANO, Sergio MALLART, Claire MINOLETTI-HOCHEPIED, Elisabetta BIANCHI, Raffaele INGENITO, Paola MAGOTTI, Alessia SANTOPRETE
  • Publication number: 20190233495
    Abstract: The present invention relates to a biologically active single chain Relaxin peptide having the following formula (I) (SEQ ID NO:65): Nter-X-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(X34)d-NH2-Cter It also concerns a pharmaceutical composition comprising at least one peptide of the invention, or a pharmaceutically acceptable salt or a solvate thereof, and the peptide, a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition, for its use as a medicament.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 1, 2019
    Inventors: Stéphane ILLIANO, Sergio MALLART, Claire MINOLETTI-HOCHEPIED, Frank MARGUET, Olivier DUCLOS, Elisabetta BIANCHI, Raffaele INGENITO, Paola MAGOTTI, Alessia SANTOPRETE
  • Publication number: 20190233493
    Abstract: The present invention relates to a biologically active single chain Relaxin peptide having the following formula (I): Nter-Ac-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(K)d-(X35)e-(gE)f-X37-Cter; or a salt or solvate thereof. It also concerns a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 1, 2019
    Inventors: Denis Brasseur, Olivier Duclos, Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Frank Marguet, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete